Phase II trial of thalidomide in renal-cell carcinoma

• Published in: Annals of oncology Vol. 13; no. 7; pp. 1029 - 1035
• Main Authors: Escudier, B., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N., Laplanche, A.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.07.2002
• Subjects: Adult; Age Factors; Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antineoplastic agents; Biological and medical sciences; Biomarkers, Tumor - analysis; Biopsy, Needle; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Chemotherapy; Confidence Intervals; Cytokines - analysis; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Key words: anti-angiogenic drugs; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Male; Medical sciences; Middle Aged; Monitoring, Physiologic - methods; Neoplasm Staging; Odds Ratio; Pharmacology. Drug treatments; renal cancer; Sex Factors; Survival Rate; thalidomide; Thalidomide - administration & dosage; Thalidomide - adverse effects; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler; Kidney disease; Antineoplastic agent; Human; Urinary system disease; Carcinoma; Toxicity; Treatment efficiency; Malignant tumor; Increasing dose; Chemotherapy; Treatment; Phase II trial; Grawitz tumor; Metastatic; Antiangiogenic agent; Thalidomide

Background: Thalidomide has been reported to yield anti-tumor activity in cancer. We performed a phase II trial of this drug in patients with metastatic renal cell carcinoma to determine its efficacy. Patients and methods: Patients with proven metastatic renal cell cancer, measurable progressive dis...